We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+2.41%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
Cap. Flow
-$50.4M
Cap. Flow %
-20.81%
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$6.87M
2
ETNB
89bio
ETNB
+$5.71M
3
KALV
KalVista Pharmaceuticals
KALV
+$5.4M
4
COGT icon
Cogent Biosciences
COGT
+$5.12M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.07M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$10.9M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.4M
3
IMVT icon
Immunovant
IMVT
+$9.22M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.8M
5
BLU
BELLUS Health Inc.
BLU
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Miscellaneous 8.14%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$12.3M 5.08%
668,784
+394,080
+143% +$6.87M
MGNX icon
2
MacroGenics
MGNX
$263M
$9.76M 4.03%
1,361,809
+749,334
+122% +$4.51M
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
$9.67M 3.99%
2,793,748
+388,388
+16% +$1.64M
PSTX
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$8.28M 3.42%
2,689,301
+459,301
+21% +$2.75M
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.37B
$8.18M 3.38%
1,435,945
+199,649
+16% +$1.04M
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$7.91M 3.26%
667,922
-32,078
-5% -$307K
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$7.75M 3.2%
202,561
+30,461
+18% +$1.36M
NUVL
8
DELISTED
Nuvalent
NUVL
$7.35M 3.03%
281,533
-21,430
-7% -$634K
BLU
9
DELISTED
BELLUS Health Inc.
BLU
$7.2M 2.97%
1,000,000
-707,370
-41% -$5.49M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.77M 2.79%
125,035
-15,331
-11% -$741K
ETNB
11
DELISTED
89bio
ETNB
$6.67M 2.76%
+438,215
New +$5.71M
VKTX icon
12
Viking Therapeutics
VKTX
$3.75B
$6.33M 2.61%
+380,000
New +$3.93M
COGT icon
13
Cogent Biosciences
COGT
$6.02B
$6.25M 2.58%
579,264
+400,264
+224% +$5.12M
KPTI icon
14
Karyopharm Therapeutics
KPTI
$42.4M
$6M 2.48%
+102,762
New +$5.07M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$5.69M 2.35%
+723,544
New +$5.4M
SDGR icon
16
Schrodinger
SDGR
$1.47B
$5.6M 2.31%
212,825
+104,825
+97% +$2.49M
PLRX icon
17
CALL
Pliant Therapeutics
PLRX
$68.7M
$5.31M 2.19%
+199,600
New +$5.68M
ACRS icon
18
CALL
Aclaris Therapeutics
ACRS
$885M
$5.27M 2.18%
+651,400
New +$8.27M
GILD icon
19
Gilead Sciences
GILD
$181B
$4.99M 2.06%
60,130
+8,168
+16% +$677K
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.82M 1.99%
577,757
+305,584
+112% +$2.94M
VCYT icon
21
Veracyte
VCYT
$3.48B
$4.68M 1.93%
209,653
+9,653
+5% +$233K
PHVS icon
22
Pharvaris
PHVS
$2.48B
$4.51M 1.86%
559,387
+459,387
+459% +$4.04M
IMGN
23
CALL
DELISTED
Immunogen Inc
IMGN
$4.33M 1.79%
1,128,200
+896,200
+386% +$3.82M
UTHR icon
24
United Therapeutics
UTHR
$22.1B
$4.16M 1.72%
18,578
+2,530
+16% +$624K
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$137B
$4.15M 1.71%
13,181
+1,797
+16% +$539K
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Silverarc Capital Management withdrew a net $50.4M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.

  • Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
  • Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
  • Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
  • Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
  • Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
  • Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
  • Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.

Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.